Pith. sign in

REVIEW 5 major objections 4 minor 46 references

Impact of the WHO's 90-70-90 Strategy on HPV-Related Cervical Cancer Control: A Mathematical Model Evaluation in China

T0 review · 5 major / 4 minor · reviewed 2026-08-07 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read This paper claims that if China reaches 70% screening and 90% treatment coverage by 2030, new cervical cancer cases will fall to zero by 2061, and by 2059 under full 90-70-90 implementation.

desk verdict A competent compartmental modeling exercise undercut by a unit-confusion in the headline 90-70-90 projections. read the letter →

arxiv 2506.06405 v1 pith:3OLF44J6 submitted 2025-06-06 q-bio.PE

Hua Liu , Chunya Liu , Yumei Wei , Qibin Zhang , Jingyan Ma This is my paper
classification q-bio.PE MSC 92D3034D2334C2349K1592C60
keywords cervicalcancerHPV90-70-90strategycompartmentalmodelbasicreproductionnumberMCMCparameterestimationoptimalcontrolChina
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

China's cervical cancer burden is still rising because the HPV vaccine arrived only in 2016, so the paper asks whether the WHO's 90-70-90 targets—90% vaccination of girls by age 15, 70% screening, 90% treatment—can reverse the trend, and which target matters most. The paper's central claim is that screening and treatment are the decisive levers: if China hits the 70% screening and 90% treatment targets by 2030, new cervical cancer cases will reach zero by 2061, and full 90-70-90 would move that date to 2059. This matters because it suggests that limited resources should be spent on the screening-treatment pair first, a priority that matches China's own 2023-2030 action plan, rather than waiting for vaccination cohorts to mature. The modeling also estimates that HPV transmission in China, measured by the basic reproduction number $R_0$, fell from 1.5026 before vaccination to 1.0726 after, a 28.62% drop.

What carries the argument

The engine is a deterministic compartmental model whose states track vaccinated, susceptible, unaware HPV carriers, precancerous, invasive cancer, and recovered individuals, all aged 15-64. The WHO targets enter directly as transition rates: 90% of girls are vaccinated on recruitment, 70% of unaware carriers are screened per unit time, and 90% of precancerous and cancer patients are treated per unit time. The basic reproduction number $R_0$, obtained from a next-generation matrix calculation, decomposes into an unaware-carrier component and a precancerous-patient component, showing where transmission persists. Sensitivity analysis identifies the screening rate $\theta$ as the most powerful non-vaccination lever, and an optimal-control version with vaccination and screening controls yields the timing of when to apply each measure.

What would settle it

Watch the next decade: if screening coverage actually reaches 70% and treatment 90% by 2030 and the observed age-specific incidence does not bend downward on a trajectory consistent with zero new cases by 2061, the central claim fails. The sharper test is mechanistic: replace the per-unit-time transition rates with an explicit screening schedule—say, 70% of eligible women screened once every three years—and rerun the same fitted model; if the zero-case year shifts substantially from 2061/2059, then the claimed dates depend on an uncalibrated rate rather than on the coverage targets themselves.

Watch

Extended reading notes

Core claim

The paper develops a six-compartment ordinary differential equation model ($V$, $S$, $I_u$, $P$, $C$, $R$) for sexually active women aged 15-64, fits it by adaptive Markov-chain Monte Carlo to China's 1990-2021 cervical cancer case and death counts, and then embeds the WHO targets as transition rates. Its central discovery is that no single 90-70-90 target eliminates cervical cancer; the 70% screening plus 90% treatment combination does, and it does so almost as fast as the full strategy: zero new cases by 2061 for the screening-treatment pair, and by 2059 under full 90-70-90. Reaching only the vaccination target, or vaccination plus one other target, leaves new cases circulating for decades, partly because vaccinated girls take 10-15 years to age into the cervical-cancer risk window. The paper also establishes the model's mathematical behavior—local and global stability of both disease-free and endemic equilibria and a forward bifurcation at $R_0=1$—and its optimal-control analysis finds that universal vaccination plus screening gives the fastest long-term control, while adult-female vaccination plus screening is the most cost-effective under resource constraints.

Load-bearing premise

The load-bearing premise is that the WHO coverage percentages can be modeled as rates—70% of unaware HPV carriers screened per unit time and 90% of precancerous and cancer patients treated per unit time—with the unit of time never specified or calibrated against observed screening intervals and treatment delays.

Editorial extensions

If this is right

  • If China reaches 70% screening and 90% treatment by 2030, the model projects zero new cervical cancer cases by 2061; full 90-70-90 moves the date to 2059.
  • Prioritizing the 70-90 combination gives nearly the same elimination timing as the full strategy, so the paper concludes it is the most cost-effective use of resources under budget limits.
  • Vaccination alone, or any single 90-70-90 target, is not enough to eliminate new cases; by 2040 the vaccine avoids 42.41% of new cases and 33.83% of deaths relative to no vaccine, but the decline arrives only after vaccinated cohorts reach cancer-prone ages.
  • Adult catch-up vaccination plus screening emerges from the optimal-control analysis as the strongest affordable combination when resources are constrained, while universal vaccination plus screening is the fastest control when resources allow.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • Beyond the paper, the unspecified time unit in the 70% screening and 90% treatment rates is a natural stress test: converting '70% coverage' into a one-per-year, once-per-three-year, or once-per-five-year screening schedule changes the effective transition rate and likely shifts the 2061/2059 zero-case dates.
  • Beyond the paper, the cost-effectiveness ordering is specific to China's situation of late vaccine introduction and still-low screening coverage; in a population with high adolescent vaccine coverage but weak screening, the screening-treatment-first conclusion would not automatically transfer.
  • Beyond the paper, treating 90% of patients as a per-unit-time exit from $P$ and $C$ assumes treated disease is cured and does not recur; adding recurrence or re-infection compartments would test whether the zero-case trajectory is robust.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

5 major / 4 minor

Summary. The paper develops a six-compartment ordinary differential equation model for HPV-induced cervical cancer in China, with compartments for vaccinated, susceptible, unaware HPV carriers, precancerous patients, cancer patients, and recovered individuals, plus vaccination, screening, treatment, and natural/cancer mortality. The authors prove positivity, boundedness, compute the basic reproduction number via the next-generation matrix, prove local and global stability of the disease-free and endemic equilibria, and show a forward bifurcation. They fit the model to GBD data for China from 1990 to 2021 using MCMC, estimate R0 before and after vaccine introduction, perform sensitivity analyses, then simulate scenarios in which the WHO 90-70-90 targets are achieved by 2030. The headline finding is that achieving 70% screening and 90% treatment by 2030 yields zero new cervical cancer cases by 2061, and full 90-70-90 yields zero by 2059; they also present an optimal control analysis of vaccination and screening strategies.

Significance. If the projections were supported, the manuscript would provide a directly usable policy message for cervical cancer elimination in China, and the fitted compartmental model with R0 estimates and stability analysis would be a useful contribution to the HPV modeling literature. The paper gives credit for a substantial modeling effort: the model includes adult catch-up vaccination and screening/treatment pathways, the MCMC fit to national incidence and mortality data is a reasonable exercise, the sensitivity analysis is informative, and the optimal control formulation is standard. However, the two headline dates (2061 and 2059) and the cost-effectiveness claim rest on an unjustified conversion of WHO coverage targets into per-unit-time transition rates and on an undefined notion of 'zero cases' in a continuous-time ODE. These are load-bearing problems, not presentation issues, so the central policy conclusion is not currently established.

major comments (5)
  1. [§4.3 and Fig. 13] The translation of the WHO 90-70-90 targets into model transition rates in §4.3 and Fig. 13 is not justified. The targets are coverage proportions: 70% of women screened by ages 35 and 45, and 90% of diagnosed women treated; they are not per-capita per-unit-time rates. The text writes '70% of those unaware of their infection are screened per unit time' and '90% × 1/unit time × P', but no time interval is specified. Since all other parameters in Table S1 are per year, an implicit unit of one year gives a screening rate of 0.7/yr, whereas a defensible conversion of 70% coverage over a 10-year screening round is −ln(0.3)/10 ≈ 0.12/yr. The elimination dates 2061 and 2059 are determined by this arbitrary choice, so the headline projection has no evidential basis.
  2. [§4.3 and Figs. 14–17] Figs. 14–17 report exact calendar years at which new cervical cancer cases reach zero, but in the continuous-time ODE (1) with R0<1 the infected compartments decay exponentially and only approach zero asymptotically; exact zero is never attained in finite time. A meaningful zero-case date requires defining an incidence threshold (e.g., less than one case per 100,000 woman-years) and, ideally, a stochastic or discrete-time formulation. Without such a threshold, the claimed 2061/2059 dates are not well-defined outputs of the model.
  3. [§4.2 and Table S1] The post-vaccination basic reproduction number R0 = 1.0726 (95% CI: 0.9384–1.2067) is presented as evidence that vaccination reduced transmission by 28.62%, but Table S1 estimates the vaccine parameters u, η, and ω from the same 1990–2021 incidence and mortality time series. Since HPV vaccination protects against infection years before it affects cervical cancer incidence, the five years of post-2016 cancer data contain almost no information about these vaccine parameters; the paper does not report identifiability diagnostics or external priors for u, η, and ω. This makes the post-vaccination R0 and the reported reduction an artifact of the fitting procedure rather than an empirical estimate.
  4. [Abstract and §4.3] The paper states that prioritizing the 70-90 target combination is 'the most cost-effective approach,' but no cost-effectiveness analysis is actually performed. Case 6 is selected because it reaches zero cases in 2061 without the vaccination target, yet the Case 1–7 comparison does not attach costs to screening, treatment, or vaccination. The cost weights in §5.2 belong to the optimal-control objective and are not used for the Case 1–7 comparison. The claim therefore conflates 'fewest required interventions' with 'most cost-effective' and should either be removed or replaced by a proper incremental cost-effectiveness analysis.
  5. [§3.3, proof of Theorem 6] The proof of the global asymptotic stability of the endemic equilibrium is incomplete. After analyzing Case 2, the text states: 'For the sake of simplicity, according to the approach used to estimate the measure μ, the analysis of the remaining cases can be omitted.' As written, Theorem 6 is not proved; the authors should either provide the full case analysis or explicitly reformulate the result as conditional on the omitted estimates.
minor comments (4)
  1. [References] References [34] and [35] appear to be the same paper by Gumel, McCluskey, and Watmough (2006), with different titles; they should be merged or corrected.
  2. [§5.1] The notation is confusing because the parameter u (adolescent vaccination fraction) and the control variables u1(t), u2(t), u3(t) coexist in the same section; please use distinct symbols for the fixed parameter and the time-varying controls.
  3. [Eq. (9)] The formula for R0 contains unbalanced parentheses in the second term as typeset, which makes it difficult to verify the derivation; please reformat.
  4. [Introduction] The sentence 'In December 2020, the Chinese government of China announced its support' is redundant; 'of China' should be deleted.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: the central parameter estimation, stability analysis, and 90-70-90 scenario projections are self-contained; self-citations are not load-bearing.

full rationale

The paper's central derivation chain is not circular. Model (1) is a standard compartmental ODE; the basic reproduction number R0 is derived from the next-generation matrix (Eqs. 7-9), and stability results are proven from the model equations. Parameters are estimated by MCMC fitting to external IHME incidence and mortality data (1990-2021), and R0 values are posterior summaries of those fits, not fitted to the claims they support. The 90-70-90 scenario in Section 4.3 imposes coverage targets as transition rates (e.g., '70% of those unaware of their infection are screened per unit time'); this is an explicit modeling assumption, not a parameter fitted to the target outcome, so the projected elimination dates are consequences of the scenario rather than circular reductions. The sensitivity analysis and 'screening reduces R0' statements are mathematical properties of the fitted model and are presented as model outputs, not as independent empirical confirmations. The only overlapping-author citations (refs [7] and [20]) support background statements about vaccine timing and prior HPV modeling; they are not used to justify the model's predictions or to forbid alternatives. The weakest point—converting WHO coverage percentages into per-unit-time rates without specifying the interval—is a correctness/calibration risk, not a circularity, and does not make the derivation equivalent to its inputs by construction.

Assumptions & free parameters 19 free parameters · 4 assumptions · 0 invented entities

The central projections rest on 19 fitted or hand-set parameters, including 11 transmission and progression rates, 4 initial conditions, the two ad hoc 90-70-90 rate conversions, and cost weights. The stability and bifurcation theorems rely on standard dynamical systems tools. No new biological entities are postulated.

free parameters (19)
  • beta_1 (transmission rate from unaware HPV carriers) = 0.18447 (pre-vaccine); 0.40850 (post-vaccine)
    Fitted by MCMC to GBD national cervical cancer case and death counts, 1990-2021. Central to R0 estimate.
  • beta_2 (transmission rate from precancerous patients) = 0.10936; 0.10697
    Fitted by MCMC; enters second term of R0.
  • sigma (screened Iu fraction progressing to cancer) = 0.01637; 0.00634
    Fitted by MCMC; controls transition from Iu to C via screening.
  • theta (screening rate) = 0.11071; 0.35502
    Fitted by MCMC; key intervention parameter in sensitivity analysis.
  • phi (screened Iu fraction progressing to precancer) = 0.16818; 0.14241
    Fitted by MCMC; affects P transition.
  • epsilon (recovery rate from precancer) = 0.72317; 0.83167
    Fitted by MCMC; negatively correlated with R0.
  • tau (progression rate from P to C) = 0.01346; 0.00574
    Fitted by MCMC; central to cervical cancer incidence.
  • d (cervical cancer mortality rate) = 0.00402; 0.00035
    Fitted by MCMC; drives death projections.
  • u (adolescent vaccination fraction) = 0.15963
    Fitted post-vaccination model; cannot be identified from 2016-2021 cancer data because vaccine effects take decades.
  • eta (adult catch-up vaccination rate) = 0.00098
    Fitted post-vaccination model; affects V compartment.
  • omega (vaccine waning rate) = 0.04133
    Fitted post-vaccination model; affects duration of vaccine protection.
  • S(0) initial susceptible population = 3.41E+08
    Fitted by MCMC as a free initial condition.
  • Iu(0) initial unaware HPV carriers = 8.47E+05
    Fitted by MCMC as a free initial condition.
  • P(0) initial precancerous patients = 1.33E+05
    Fitted by MCMC as a free initial condition.
  • R(0) initial recovered population = 2.79E+07
    Fitted by MCMC as a free initial condition.
  • Screening target rate (70% per unit time) = 0.7 (unit unspecified)
    Chosen ad hoc in Section 4.3, Fig. 13 to represent the WHO 70% screening coverage target; time unit is not specified.
  • Treatment target rate (90% per unit time) = 0.9 (unit unspecified)
    Chosen ad hoc in Section 4.3, Fig. 13 to represent the WHO 90% treatment coverage target; time unit is not specified.
  • screen_period and treatment_period = set implicitly to 1 (unit unspecified)
    Fig. 13 uses '1/screen period' and '1/treatment period' rates without defining the period; this determines the zero-case years.
  • Optimal control cost weights = A1=4000, A2=2000, A3=500, B2=15000, B3=150000, B1=A3
    Selected from price references; not fitted. They drive the 'most cost-effective' conclusion in Section 5.
assumptions (4)
  • standard math Standard stability criteria (Routh-Hurwitz, LaSalle invariance, center manifold, Pontryagin maximum principle) are valid and applicable to Model (1).
    Invoked in Theorems 2, 3, 4, 6, 7 and Section 5.1.
  • domain assumption The sexually active female population aged 15-64 is homogeneously mixed, with constant recruitment and no age or sexual-activity structure.
    Model (1) and Fig. 1 assume mass-action transmission and constant recruitment Lambda.
  • ad hoc to paper Screening coverage targets of the 90-70-90 strategy can be represented as per-unit-time transition rates (70% of Iu screened per unit time, 90% of P treated per unit time) in the model.
    Section 4.3 and Fig. 13 introduce this equivalence without specifying the time unit; the zero-case year depends on it.
  • ad hoc to paper Vaccination-related parameters u, eta, omega can be identified from 1990-2021 national cervical cancer case and death counts, even though vaccination effects on cervical cancer take decades.
    MCMC fits these parameters to case and death data where vaccine effects could not yet appear; Section 4, Table S1.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Impact of the WHO's 90-70-90 Strategy on HPV-Related Cervical Cancer Control: A Mathematical Model Evaluation in China." pith.science (2026). https://pith.science/paper/3OLF44J6

@misc{pith2026250606405,
  author       = {Pith},
  title        = {Pith review of: Impact of the WHO's 90-70-90 Strategy on HPV-Related Cervical Cancer Control: A Mathematical Model Evaluation in China},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/3OLF44J6}},
  note         = {Machine review of arXiv:2506.06405}
}
read the original abstract

In August 2020, the World Health Assembly approved the Global Strategy to eliminate cervical cancer, marking the first time that numerous countries committed to eliminating a form of cancer. China introduced the HPV vaccine in 2016 and has made significant advancements in both prevention and treatment strategies. However, due to the relatively late introduction of the vaccine, the burden of cervical cancer in China continues to rise. In light of this, we develop a compartmental model to assess the impact of the WHO's 90-70-90 strategy, along with adult catch-up vaccination, on the control of HPV-induced cervical cancer in China. We analyze the basic properties of the model and provide proofs of the local and global asymptotic stability of the equilibrium points. Additionally, a sensitivity analysis is performed, and we use the MCMC algorithm to fit the number of new cervical cancer cases and deaths in China from 1990 to 2021. The estimated basic reproduction number before and after the introduction of the HPV vaccine in China is 1.5026 (95% CI: 1.4051-1.6002) and 1.0726 (95% CI: 0.9384-1.2067), respectively. The sensitivity analysis reveals that screening, as a non-pharmaceutical intervention, plays a crucial role in controlling the spread of the disease. We apply the 90-70-90 strategy to predict the future number of new cervical cancer cases and deaths in China. The results indicate that prioritizing the 70-90 target combination is the most cost-effective approach and can achieve the goal of zero new cervical cancer cases by 2061. Finally, an optimal control model is developed to explore the best implementation strategies for HPV vaccination and screening under various plausible scenarios.

Discussion (0). Sign in to comment.

Reference graph

Works this paper leans on

46 extracted references · 43 canonical work pages

  1. [1]

    E., Einstein, M

    Castle, P. E., Einstein, M. H., & Sahasrabuddhe, V . V . (2021). Cervical cancer prevention and control in women living with human immunodeficiency virus. CA: A Cancer Journal for Clinicians, 71(6), 505–526. https://doi.org/10.3322/caac.21696

    work page doi:10.3322/caac.21696 2021

  2. [2]

    World Health Or ganization. (2014). Comprehensive cervical cancer control: A guide to essential practice (2nd ed.). World Health Organization

    work page 2014

  3. [3]

    M., & Rajkumar, R

    Sankaranarayanan, R., Budukh, A. M., & Rajkumar, R. (2001). Effective screening programmes for cervical cancer in low - and middle-income developing countries. Bulletin of the World Health Organization, 79(10), 954–962

    work page 2001

  4. [4]

    R., Abbas, A., Chunara , R., Manji, A

    Chughtai, N., Perveen, K., Gillani, S. R., Abbas, A., Chunara , R., Manji, A. A., et al. (2023). National cervical cancer burden estimation through systematic review and analysis of publicly available data in Pakistan. BMC Public Health , 23(1), Article 834. https://doi.org/10.1186/s12889-023-15531-z

    work page doi:10.1186/s12889-023-15531-z 2023

  5. [5]

    J., Gómez, D., et al

    Bruni, L., Albero, G., Serrano, B., Mena, M., Collado, J. J., Gómez, D., et al. (2023). Human Papillomavirus and Related Diseases in China. Barcelona: ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Retrieved from https://hpvcentre.net/statistics/reports/CHN.pdf. Accessed January 8, 2025

    work page 2023

  6. [6]

    Herrero, R., González, P., & Markowitz, L. E. (2015). Present status of human papillomavirus vaccine development and implementation. Lancet Oncology , 16(5), e206 –e216. https://doi.org/10.1016/S1470-2045(14)70481-4

    work page doi:10.1016/s1470-2045(14)70481-4 2015

  7. [7]

    Liu, C., Liu, H., Zhu, X., Lin, X., Zhang, Q., & Wei, Y . (2024). Dynamic analysis of human papillomavirus transmission model under vaccine intervention: A case study of cervical cancer patients from Hungary. Advances in Continuous and Discrete Models , 2024(1), Article 36. https://doi.org/10.1186/s13662-024-03838-z

    work page doi:10.1186/s13662-024-03838-z 2024

  8. [8]

    Deng, Y ., He, D., & Zhao, Y . (2024). Assessment of age -dependent effects during the transmission of Omicron and the outcomes of booster campaign vaccination strategies. Applied Mathematical Modelling, 133, 148–169. https://doi.org/10.1016/j.apm.2024.05.018

    work page doi:10.1016/j.apm.2024.05.018 2024

Show all 46 references
  1. [9]

    Zhang, B., Wang, S., Yang, X., Chen, M., Ren, W., Bao, Y ., & Qiao, Y . (2023). Knowledge, willingness, uptake and barriers of cervical cancer screenin g services among Chinese adult females: a national cross -sectional survey based on a large e -commerce platform. BMC Women's...

    2023 doi

  2. [10]

    The Central People's Government of the People's Republic of China. (2016). HPV vaccine for cervical cancer prevention approved in China. Retrieved from https://www.gov.cn/xinwen/2016-07/18/content_5092489.htm. Accessed January 8, 2025

    2016

  3. [11]

    L., Hu, S

    Zhao, X. L., Hu, S. Y ., Hu, J. W., Wang, H. H., Wen, T. M., Feng, Y . S., et al. (2023). Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward. Infectious Diseases of Poverty, 12(05), 81–86. https://doi.org/10.1186/s40249-023-01136-6

    2023 doi

  4. [12]

    World Health Organization. (2022). Cervical cancer elimination initiative. Retrieved from https://www.who.int/initiatives/cervical-cancer-elimination-initiative. Accessed January 8, 2025

    2022

  5. [13]

    World Health Organization. (2020). World Health Assembly adopts global strategy to accelerate cervical cancer elimination. Retrieved from https://www.who.int/news/item/19-08- 2020-world-health-assembly-adopts-global-strategy-to-accelerate-cervical-cancer-elimination. Accessed ...

    2020

  6. [14]

    World Health Organization. (2024). Immunization coverage. Retrieved from https://www.who.int/news-room/fact-sheets/detail/immunization-coverage. Accessed January 8, 2025

    2024

  7. [15]

    Global Strategy to Accelerate the Elimination of Cervical Cancer

    The Central People's Government of the People's Republic of China. (2020). China supports the "Global Strategy to Accelerate the Elimination of Cervical Cancer. " Retrieved from https://www.gov.cn/xinwen/2020-12/10/content_5568770.htm. Accessed January 8, 2025

    2020

  8. [16]

    The Central People's Government of the People's Republic of China. (2024). Notice on the issuance of the Cervical Cancer Elimination Acceleration Action Plan (2023–2030). Retrieved from https://www.gov.cn/zhengce/zhengceku/2023 -01/21/content_5738364.htm. Accessed January 8, 2025

    2024

  9. [17]

    Health Commission of Gansu Province. (2023). Notice on the issuance of the Gansu Province Cervical Cancer Elimination Acceleration Action Plan (2023 –2030). Retrieved from 36 https://wsjk.gansu.gov.cn/wsjk/c113837/202305/169847535.shtml. Accessed January 8, 2025

    2023

  10. [18]

    A., Villavicencio-Pulido, G., & Velasco-Hernandez, J

    Saldaña, F., Camacho-Gutiérrez, J. A., Villavicencio-Pulido, G., & Velasco-Hernandez, J. X. (2022). Modeling the transmission dynamics and vaccination strategies for human papillomavirus infection: An optimal control approach. Applied Mathematical Modelling, 112, 767–785. http...

    2022 doi

  11. [19]

    Choi, H. C. W., Leung, K., Chan, K. K. L., Bai, Y ., Jit, M., & Wu, J. T. (2023). Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis. BMC Medic...

    2023 doi

  12. [20]

    Liu, H., Lin, X., Zhu, X., Zhang, Q., Wei, Y ., & Ma, G. (2024). Modeling and analysis of a human papilloma virus transmission model with impact of media. Mathematical Biosciences, 375, 109247. https://doi.org/10.1016/j.mbs.2024.109247

    2024

  13. [21]

    J., Gaffikin, L., Goldhaber-Fiebert, J

    Goldie, S. J., Gaffikin, L., Goldhaber-Fiebert, J. D., Gordillo-Tobar, A., Levin, C., Mahé, C., & Wright, T. C. (2005). Cost -effectiveness of cervical -cancer screening in five developing countries. New Engla nd Journal of Medicine , 353(20), 2158 –2168. https://doi.org/10.10...

    2005 doi

  14. [22]

    J., C anfell, K., Drolet, M., Gingras, G., Burger, E

    Brisson, M., Kim, J. J., C anfell, K., Drolet, M., Gingras, G., Burger, E. A. , et al. (2016). Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models....

    2016 doi

  15. [23]

    H., Bizuayehu, H

    Hailegebireal, A. H., Bizuayehu, H. M., & Tirore, L. L. (2024). Far behind 90 -70-90’s screening target: The prevalence and determinants of cervical cancer screening among Sub - Saharan African women: Evidence from Demographic and Health Survey. BMC Cancer, 24(1), Article 1050...

    2024 doi

  16. [24]

    U., & Inyama, S

    Omame, A., Nnanna, C. U., & Inyama, S. C. (2021). Optimal control and cost -effectiveness analysis of an HPV –Chlamydia trachomatis co -infection model. Acta Biotheoretica, 69(2), 185–223. https://doi.org/10.1007/s10441-020-09401-z

    2021 doi

  17. [25]

    Zhou, J., Ye, Y ., Arenas, A., Gómez, S., & Zhao, Y . (2023). Pattern formation and bifurcation analysis of delay induced fractional-order epidemic spreading on networks. Chaos, Solitons & Fractals, 174, Article 113805. https://doi.org/10.1016/j.chaos.2023.113805

    2023

  18. [26]

    N., Schleiff, M., Muralidharan, K

    Guillaume, D., Waheed, D. N., Schleiff, M., Muralidharan, K. K., V orsters, A., & Limaye, R. J. (2024). Global perspectives of determinants influencing HPV vaccine introduction and scale- up in low - and middle -income countries. PLOS ONE , 19(1), Article e0291990. https://doi...

    2024 doi

  19. [27]

    J., Buckley, C

    Arends, M. J., Buckley, C. H., & Wells, M. (1998). Aetiology, pathogenesis, and pathology of cervical neoplasia. Journal of Clinical Pathology , 51(2), 96 –103. https://doi.org/10.1136/jcp.51.2.96

    1998 doi

  20. [28]

    The Paper. (2022). 1958 Cervical cancer screening for one million women in China. Retrieved from https://www.thepaper.cn/newsDetail_forward_17830481. Accessed January 8, 2025

    2022

  21. [29]

    The Central People's Government of the People's Republic of China. (2013). 25.41 million rural women in China have completed the free screening for ‘two cancers’ (cervical cancer and breast cancer). Retrieved from https://www.gov.cn/jrzg/2013 -10/26/content_2515898.htm. Access...

    2013

  22. [30]

    World Health Organization. (2024). Human papillomavirus and cancer. Retrieved from https://www.who.int/zh/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer. Accessed January 8, 2025

    2024

  23. [31]

    Huo, H., Chen, R., & Wang, X. (2016). Modelling and stability of HIV/AIDS epidemic model with treatment. Applied Mathematical Modelling , 40(13 –14), 6550 –6559. https://doi.org/10.1016/j.apm.2016.01.054

    2016 doi

  24. [32]

    La Salle, J. P. (1976). The Stability of Dynamical Systems. SIAM

    1976

  25. [33]

    Li, M., & Muldowney, J. S. (1996). A geometric approach to global-stability problems. SIAM Journal on Mathematical Analysis , 27(4), 1070 –1083. https://doi.org/10.1137/S0036141094266449

    1996 doi

  26. [35]

    B., Connell, M

    Gumel, A. B., Connell, M. C., & Watmough, J. (2006). An SVEIR model for assessing potential 37 impact of an imperfect anti-SARS vaccine. Mathematical Biosciences and Engineering, 3(3), 485-512 https://doi.org/10.3934/mbe.2006.3.485

    2006 doi

  27. [36]

    Castillo-Chavez, C., & Song, B. (2004). Dynamical models of tuberculosis and their applications. Mathematical Bioscienc es and Engineering , 1(2), 361 –404. https://doi.org/10.3934/mbe.2004.1.361

    2004 doi

  28. [37]

    Institute for Health Metrics and Evaluation (IHME). (2024). Global Burden of Disease Results Tool. Retrieved from https://vizhub.healthdata.org/gbd-results/. Accessed January 8, 2025

    2024

  29. [38]

    National Bureau of Statistics of China. (2024). Retrieved from https://www.stats.gov.cn/. Accessed January 8, 2025

    2024

  30. [39]

    Haario, H., Laine, M., Mira, A., & Saksman , E. (2006). DRAM: efficient adaptive MCMC. Statistics and Computing, 16, 339–354. https://doi.org/10.1007/s11222-006-9438-0

    2006 doi

  31. [40]

    China Daily. (2022). More Chinese women getting HPV vaccine in recent yea rs. Retrieved from https://www.chinadaily.com.cn/. Accessed June 6, 2025

    2022

  32. [41]

    Zhang, K., Xue, L., Li, X., He, D., & Peng, Z. (2024). Exploring the seasonality and optimal control strategy of HIV/AIDS epidemic in China: The impact of seasonal testing. Chaos: An Interdisciplinary Journal of Nonlinear Science , 34(7), Article 073111. https://doi.org/10.106...

    2024 doi

  33. [42]

    Ye, Y ., Zhou, J., & Zhao, Y . (2025). Pattern formation in reaction-diffusion information propagation model on multiplex simplicial complexes. Information Sciences, 689, 121445. https://doi.org/10.1016/j.ins.2024.121445

    2025

  34. [43]

    L., Lenhart, S., Miller, R., & Yong, J

    Kern, D. L., Lenhart, S., Miller, R., & Yong, J. (2007). Optimal control applied to native – invasive population dynamics. Journal of Biological Dynamics , 1(4), 413 –426. https://doi.org/10.1080/17513750701605556

    2007 doi

  35. [44]

    Pontryagin, P. L. S. (2018). Mathematical Theory of Optimal Processes (P. L. S. Pontryagin, Ed.). Routledge

    2018

  36. [45]

    HPV Vaccine Prices in China. (2024). Retrieved from https://www.qm120.com/pgd/n1664.html. Accessed January 8, 2025

    2024

  37. [46]

    Cervical Cancer Screening Price in China. (2023). Retrieved from https://m.baidu.com/bh/m/detail/ar_6284910037068257442. Accessed January 8, 2025

    2023

  38. [47]

    Li, H., Wang, Y ., Shen, G., Y uan, M., Liu, L., Liu, G., & Zhu, L. (2022). Economic burden of patients with cervical cancer and precancerous lesions. Preventive Medicine, 34(4), 350–356. https://doi.org/10.19485/j.cnki.issn2096-5087.2022.04.006 1 Impact of the WHO's 90-70-90 ...

    2022

Pith tools

Reviewed August 7, 2026 · model on record in the stance chip above.